Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gns Healthcare Inc. (Aitia)
Headquarters: Somerville, MA, United States of America
Website: https://www.aitiabio.com/
Year Founded: 2000
Status: Private
BioCentury | Oct 9, 2024
Product Development
How to establish causality via patient observation
Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal
BioCentury | Oct 7, 2024
Discovery & Translation
Causal biology in the age of big data
Where do you start? Patient data might sound more obvious, but human cell-based models have advantages
BioCentury | Oct 1, 2024
Deals
Prime narrows gene editing focus with BMS deal
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | Sep 5, 2024
Discovery & Translation
AI for target discovery: the start of a long road
Back to School 2024: Investments in AI in drug discovery pick up, as the picture starts to form of how target discovery may benefit
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | May 17, 2023
Regulation
May 17 Quick Takes: Intercept falls on negative tone of FDA briefing docs
Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos
BioCentury | Mar 16, 2023
Deals
March 15 Quick Takes: Rival bid could upend Redx-Jounce deal
Plus: Dermavant’s Vtama meets Phase III endpoints, and updates from CMS, Aitia, Bellicum and more
BioCentury | Jan 18, 2023
Product Development
Becoming Aitia: why GNS shifted from AI provider to drug discoverer
With John Maraganore chairing its board, the causal AI company thinks patient data has matured enough to tap more value from its technology
BioCentury | Nov 3, 2022
Management Tracks
Fantaccini becomes head of medical affairs, CSO at Novartis
Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Apr 15, 2022
Management Tracks
Sarepta veteran O’Neill becomes CEO at Editas
Plus Slapak retires from Vor, and updates from Harbour, Citius and more
Items per page:
1 - 10 of 71